34 results
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
19 Mar 24
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
6:31am
. Rescue: Participant received injected SRL and was classified as a non-responder if there were two consecutive IGF-1 ≥ 1.5x ULN on 60 mg
8-K
EX-99.2
CRNX
Crinetics Pharmaceuticals Inc
11 Sep 23
Regulation FD Disclosure
6:05am
received injected SRL and was classified as a non-responder if there were two consecutive IGF-1 ≥ 1.3 xULN on 60 mg AND exacerbation of acromegaly
8-K
EX-99.1
2xawm
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am
8-K
w7ztjqini 075o
13 Oct 22
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
8:32am